extra tirzepatide in vial Single-Dose Means One Time Use Only! Anyone else received way more

Compounded tirzepatide is a dual GLP-1/GIP receptor agonist prepared by U.S.-licensed 503A compounding pharmacies in accordance with applicable federal and state regulations

Clinical trial results discussed in this article - STEP 1 (14.9% average body weight loss with semaglutide), SURMOUNT-1 (20.9% average body weight loss with tirzepatide), and SELECT (20% reduced risk of major cardiovascular events with FDA-approved Wegovy in a specific patient population) - relate to studied active ingredients and specific FDA-approved formulations in controlled trial populations and should not be interpreted as guaranteed outcomes for any individual patient or compounded formulation

3.3 Summary of Outcomes 3.3.1 Efficacy Outcomes 3.3.1.1 HbA1c Overall, all 8 articles (Jabbour et al., 2018

It reduces glucagon release from the pancreas

Tirzepatide is available under the brand names Mounjaro and, more recently, Zepbound

A: 5-7 day half-life